Terns Pharma 8-K: Leadership Changes & Comp Arrangements
Ticker: TERN · Form: 8-K · Filed: Feb 7, 2024 · CIK: 1831363
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Terns Pharma filed an 8-K on Feb 7th for leadership and compensation changes on Feb 6th; details to follow.**
AI Summary
Terns Pharmaceuticals, Inc. filed an 8-K on February 7, 2024, reporting an event that occurred on February 6, 2024. This filing, under Item 5.02, pertains to changes in directors or officers and their compensation arrangements. While the specific details of these changes are not provided in this excerpt, such filings are crucial for investors as they signal potential shifts in leadership or executive incentives, which can impact the company's strategic direction and financial performance. Investors should monitor subsequent disclosures for the full details of these changes.
Why It Matters
Changes in executive leadership or compensation can signal strategic shifts or impact company morale and future performance, directly affecting shareholder value.
Risk Assessment
Risk Level: medium — Without specific details on the personnel changes or compensation, the impact on the company's future is uncertain, posing a moderate risk.
Analyst Insight
A smart investor would await further disclosures from Terns Pharmaceuticals, Inc. to understand the specific details of the leadership and compensation changes before making any investment decisions, as these details will clarify the potential impact on the company's future.
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- February 6, 2024 (date) — Date of Earliest Event Reported
- February 7, 2024 (date) — Date of 8-K filing
- 001-39926 (other) — Commission File Number
- TERN (other) — Trading Symbol
- Nasdaq Global Select Market (other) — Exchange where stock is registered
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 6, 2024.
What specific items are covered under this 8-K filing for Terns Pharmaceuticals, Inc.?
This 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits'.
What is the trading symbol and the exchange where Terns Pharmaceuticals, Inc. common stock is registered?
The trading symbol for Terns Pharmaceuticals, Inc. is TERN, and its common stock is registered on the Nasdaq Global Select Market.
What is the business address of Terns Pharmaceuticals, Inc. as stated in the filing?
The business address of Terns Pharmaceuticals, Inc. is 1065 East Hillsdale Blvd. Suite 100, Foster City, California, 94404.
What is the purpose of an 8-K filing according to the document?
The 8-K filing is a 'CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934'.
Filing Stats: 1,993 words · 8 min read · ~7 pages · Grade level 12.1 · Accepted 2024-02-07 16:20:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TERN Nasdaq Glo
- $625,000 — ve a starting annualized base salary of $625,000, and is eligible to receive an annual c
- $15,000 — Burroughs Agreement up to an amount of $15,000. In accordance with the Burroughs Agr
- $15.00 — secutive trading days equals or exceeds $15.00 per share and as to the remaining 50% o
- $20.00 — secutive trading days equals or exceeds $20.00 per share, subject to Ms. Burroughs' co
Filing Documents
- d718313d8k.htm (8-K) — 38KB
- d718313dex991.htm (EX-99.1) — 10KB
- 0001193125-24-026712.txt ( ) — 183KB
- tern-20240206.xsd (EX-101.SCH) — 3KB
- tern-20240206_lab.xml (EX-101.LAB) — 19KB
- tern-20240206_pre.xml (EX-101.PRE) — 12KB
- d718313d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by Terns Pharmaceuticals, Inc. on February 7, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 7, 2024 TERN PHARMACEUTICALS, INC. By: /s/ Bryan Yoon Bryan Yoon Chief Operating Officer & General Counsel